£1,000 to invest? I’d buy this FTSE 250 income stock, but approach another with caution

Harvey Jones tips a top FTSE 250 (INDEXFTSE:UKX) growth and income stock, but isn’t ready to buy another recovery play.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Private hospital group Mediclinic International (LSE: MDC) has had a rough time since listing on the London market in 2016.

In poor health

It was briefly a constituent of the FTSE 100, but with its share price down 60% in the last three years, it now languishes in the FTSE 250 with a market-cap of £2.7bn.

The Mediclinic share price is up 2% today after markets smiled on its 2020 half-year trading update. Group CEO Dr Ronnie van der Merwe reported an encouraging performance with trading in line with expectations, as it expands across all three of its divisions.

He also highlighted good revenue growth, broadly stable margins in Switzerland, patient volumes in line with expectations at Mediclinic Southern Africa, and “continued gradual improvement” in the Abu Dhabi business.

Road to recovery

The group’s problems were down to impairment charges totalling £262m on its UK and Swiss businesses, which struggled with government regulation and increased competition, even as its South African and Middle East operations reported steady revenue growth. Yet private healthcare is a relatively defensive market and investors have been looking for an opportunity to buy back into the growth story.

Given its troubles, I would have expected the Mediclinic share price to be trading at a wider discount and just 13.5 times forecast earnings. The forecast yield is just 2.1%, although nicely covered 3.4 times, giving scope for growth. Earnings are predicted to fall 4% this year, but the future looks brighter as City analysts reckon they could climb 11% next year.

It is well worth keeping an eye on Mediclinic, but I wouldn’t rush to buy it today. Especially when there are so many exciting stocks on the FTSE 250 at the moment, including this little gem picked it by my fellow Fool writer Alan Oscroft, which also operates in the healthcare sector.

In rude health

Earlier this month, Alan wrote that Primary Health Properties (LSE: PHP) offers a tempting combination of strong share price growth and high dividends. The growth has been eye-popping, up 30% in the last year, and almost 70% over years.

The £1.67bn company invests in healthcare real estate in the UK and Ireland, which it lets out on long-term leases backed by a secure underlying covenant, with the majority of rental income funded either directly or indirectly by a government body.

The primary healthcare real estate sector is typically less cyclical than other parts of the property market, which makes Primary Health Properties surprisingly low risk, given recent soaraway growth. I can see why Alan admires it.

Low risk, high price

Last month, it launched a share placing to raise £75m to fund further expansion, as it sees attractive investment opportunities in building larger GP primary care centres. This is on top of the £60m it has already committed to fund the acquisition and development of eight medical centres, and £70m on other medical centres as it looks to boost the number of assets in its portfolio.

Today, it offers an attractive forward yield of 4%. Earnings growth looks steady at a forecast 10% this year, and 7% next. There is one downside, though. Alan isn’t the first to spot an opportunity here. The stock is a little pricey at 23.7 times earnings. Sometimes you have to pay for quality…

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has recommended Primary Health Properties. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »